ClinicalTrials.gg
RecruitingNCT07076966Updated Sep 29, 2026

Comparison of Adenoma Detection Rate in 3D vs. 2D Surveillance Colonoscopy

An interventional study of 3D device in Colonoscopy, Adenoma Detection Rate and Three Dimensional, sponsored by National Taiwan University Hospital. Recruiting at 3 sites in Taiwan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2024, registered Oct 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Sep 29, 2026Enrollment updated3 sites added+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

There is substantial evidence confirming that identifying and removing colorectal adenomas during colonoscopy helps prevent the development of colorectal cancer. Among the quality indicators for colonoscopy, adenoma detection rate (ADR) is the most important, as it is closely related to the patient's future risk of colorectal cancer. Recent studies have further demonstrated that improving ADR can reduce future mortality from colorectal cancer. Notably, non-polypoid lesions (such as flat or depressed lesions) are more likely to be missed during traditional colonoscopy, making these lesions a leading cause of post-colonoscopy interval colorectal cancer.

In a prospective trial conducted by our team comparing the ADR of 3D colonoscopy with standard 2D colonoscopy, we found that 3D colonoscopy significantly improved overall ADR and the detection rate of non-polypoid adenomas.

According to current international guidelines, after an index colonoscopy, patients are recommended to undergo surveillance colonoscopy 1 to 10 years later, depending on their findings at index colonoscopy. Since these patients represent the majority in clinical practice, increasing the ADR during surveillance colonoscopy not only allows for more precise recommendations for the timing of the next colonoscopy but also effectively reduces the risk of post-colonoscopy colorectal cancer (PCCRC).

Therefore, this multicenter, prospective, randomized trial aims to compare the clinical performance of 3D colonoscopy and standard 2D colonoscopy in the context of surveillance colonoscopy.

02

Conditions studied

  • Colonoscopy
  • Adenoma Detection Rate
  • Three Dimensional
  • Colon Polyps and Adenomas

Keywords

  • Colonoscopy
  • adenoma detection rate
  • 3D
  • surveillance colonoscopy
03

In context

Colonic Polyps

377 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's planned enrollment of 660 is above the median of 274 across 250 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are 40 years of older
  • Subjects who receive colonoscopy and polypectomy more the 1 year
  • Subjects who need surveillance colonoscopy

Exclusion criteria

Exclusion Criteria:

  • for colonoscopy
  • Subjects with familiar or hereditary polyposis
  • Subjects with history of colectomy
  • Inadequate bowel cleansing level
  • Subjects with inflammatory bowel disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    3D colonoscopy

    Device: 3D device

  • No intervention
    2D colonoscopy

Interventions

  • Device3D device

    Use 3D machine to generate the 3D image

06

What researchers measure

Primary outcomes

  1. Adenoma detection rate

    Time frame: 30 minutes

Secondary outcomes

  1. Flat-ADR

    detection rate of flat adenoma

    Time frame: 30 minutes

  2. Proximal ADR

    detection rate of adenoma at proximal colon

    Time frame: 30 minutes

  3. Distal ADR

    detection rate of adenoma at distal colon

    Time frame: 30 minutes

  4. SSLDR

    detection rate of sessile serrated lesion

    Time frame: 30 minutes

  5. AADR

    detection rate of advanced adenoma

    Time frame: 30 minutes

  6. Detection of of adenoma with various size

    Time frame: 30 minutes

  7. Polyp detection rate

    Time frame: 30 minutes

  8. Adenoma number per colonoscopy,

    Time frame: 30 minutes

  9. Polyp number per colonoscopy

    Time frame: 30 minutes

07

Study locations

3 of 3 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 Taiwan)
  • National Taiwan University Hospital, Hsinchu Branch · Hsinchu, Taiwan
  • National Taiwan University Cancer Center · Taipei, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
Show 3 removed
  • National Taiwan University Hospital, Hsinchu Branch · Hsinchu, Taiwan
  • National Taiwan University Cancer Center · Taipei, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
Sep 29, 2026
Enrollment
500→660
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 Taiwan)
    • National Taiwan University Hospital, Hsinchu Branch · Hsinchu, Taiwan
    • National Taiwan University Cancer Center · Taipei, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    Show 3 removed
    • National Taiwan University Hospital, Hsinchu Branch · Hsinchu, Taiwan
    • National Taiwan University Cancer Center · Taipei, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    Enrollment 500→660
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07076966
Responsible party
Statistical Center, NTUHCTC (Attending physician, Department of Internal Medicine, National Taiwan University Hospital) — Principal investigator
First posted
Jul 22, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Li-Chun Chang, MD. PhD.
Contact
lichunchang@ntu.edu.tw
886-9-72-651-258

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion